As occurs in PCOS women, DHT treatment in PCOS-like female boosts NAFLD progression and liver degeneration by increasing the activation of NF-κB signaling, enhancing the gene expression of pro-inflammatory markers such as Il-6, Il-1β, and Tnfα, and by reducing the expression of pro-apoptotic markers such as LC3II (microtubule-associated protein light chain 3), thus negatively impacting on the hepatic ability to regenerate [191]. The gene discussed is IL1B; the disease is metabolic dysfunction-associated steatotic liver disease.